Literature DB >> 32328695

Congenital Conditions of Hypophosphatemia in Children.

Erik Allen Imel1.   

Abstract

Great strides over the past few decades have increased our understanding of the pathophysiology of hypophosphatemic disorders. Phosphate is critically important to a variety of physiologic processes, including skeletal growth, development and mineralization, as well as DNA, RNA, phospholipids, and signaling pathways. Consequently, hypophosphatemic disorders have effects on multiple systems, and may cause a variety of nonspecific signs and symptoms. The acute effects of hypophosphatemia include neuromuscular symptoms and compromise. However, the dominant effects of chronic hypophosphatemia are the effects on musculoskeletal function including rickets, osteomalacia and impaired growth during childhood. While the most common causes of chronic hypophosphatemia in children are congenital, some acquired conditions also result in hypophosphatemia during childhood through a variety of mechanisms. Improved understanding of the pathophysiology of these congenital conditions has led to novel therapeutic approaches. This article will review the pathophysiologic causes of congenital hypophosphatemia, their clinical consequences and medical therapy.

Entities:  

Keywords:  FGF23; Fibroblast growth factor 23; Hypophosphatemia; Rickets; XLH

Mesh:

Substances:

Year:  2020        PMID: 32328695      PMCID: PMC7581541          DOI: 10.1007/s00223-020-00692-5

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  121 in total

Review 1.  Hearing impairment in familial X-linked hypophosphatemic rickets.

Authors:  Gadi Fishman; Denise Miller-Hansen; Cynthia Jacobsen; Virender K Singhal; Uri S Alon
Journal:  Eur J Pediatr       Date:  2004-10       Impact factor: 3.183

2.  Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.

Authors:  Erik A Imel; Francis H Glorieux; Michael P Whyte; Craig F Munns; Leanne M Ward; Ola Nilsson; Jill H Simmons; Raja Padidela; Noriyuki Namba; Hae Il Cheong; Pisit Pitukcheewanont; Etienne Sochett; Wolfgang Högler; Koji Muroya; Hiroyuki Tanaka; Gary S Gottesman; Andrew Biggin; Farzana Perwad; Meng Mao; Chao-Yin Chen; Alison Skrinar; Javier San Martin; Anthony A Portale
Journal:  Lancet       Date:  2019-05-16       Impact factor: 79.321

3.  Iron Supplementation Associated With Loss of Phenotype in Autosomal Dominant Hypophosphatemic Rickets.

Authors:  Klaus Kapelari; Julia Köhle; Dieter Kotzot; Wolfgang Högler
Journal:  J Clin Endocrinol Metab       Date:  2015-07-17       Impact factor: 5.958

4.  A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.

Authors:  Karl L Insogna; Karine Briot; Erik A Imel; Peter Kamenický; Mary D Ruppe; Anthony A Portale; Thomas Weber; Pisit Pitukcheewanont; Hae Il Cheong; Suzanne Jan de Beur; Yasuo Imanishi; Nobuaki Ito; Robin H Lachmann; Hiroyuki Tanaka; Farzana Perwad; Lin Zhang; Chao-Yin Chen; Christina Theodore-Oklota; Matt Mealiffe; Javier San Martin; Thomas O Carpenter
Journal:  J Bone Miner Res       Date:  2018-06-26       Impact factor: 6.741

5.  Treatment of hypophosphatemic rickets in generalized arterial calcification of infancy (GACI) without worsening of vascular calcification.

Authors:  Carlos R Ferreira; Shira G Ziegler; Ashutosh Gupta; Catherine Groden; Kevin S Hsu; William A Gahl
Journal:  Am J Med Genet A       Date:  2016-02-09       Impact factor: 2.802

6.  Craniofacial and dental characteristics of patients with vitamin-D-dependent rickets type 1A compared to controls and patients with X-linked hypophosphatemia.

Authors:  Hans Gjørup; Signe Sparre Beck-Nielsen; Dorte Haubek
Journal:  Clin Oral Investig       Date:  2017-06-12       Impact factor: 3.573

7.  Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy.

Authors:  Frank Rutsch; Petra Böyer; Yvonne Nitschke; Nico Ruf; Bettina Lorenz-Depierieux; Tanja Wittkampf; Gabriele Weissen-Plenz; Rudolf-Josef Fischer; Zulf Mughal; John W Gregory; Justin H Davies; Chantal Loirat; Tim M Strom; Dirk Schnabel; Peter Nürnberg; Robert Terkeltaub
Journal:  Circ Cardiovasc Genet       Date:  2008-12

8.  Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia.

Authors:  T O Carpenter; M A Mitnick; A Ellison; C Smith; K L Insogna
Journal:  J Clin Endocrinol Metab       Date:  1994-06       Impact factor: 5.958

9.  Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase.

Authors:  Dagmar-Christiane Fischer; Anne Mischek; Sabrina Wolf; Anja Rahn; Birgit Salweski; Guenther Kundt; Dieter Haffner
Journal:  Ann Clin Biochem       Date:  2012-09-14       Impact factor: 2.057

10.  Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.

Authors:  Yuichiro Shimizu; Yuko Tada; Mika Yamauchi; Takaaki Okamoto; Hisanori Suzuki; Nobuaki Ito; Seiji Fukumoto; Toshitsugu Sugimoto; Toshiro Fujita
Journal:  Bone       Date:  2009-06-23       Impact factor: 4.398

View more
  6 in total

1.  Phosphate Metabolism.

Authors:  Salvatore Minisola; Maria Luisa Brandi
Journal:  Calcif Tissue Int       Date:  2020-08-09       Impact factor: 4.333

Review 2.  Disorders of phosphate homeostasis in children, part 2: hypophosphatemic and hyperphosphatemic disorders.

Authors:  Richard M Shore
Journal:  Pediatr Radiol       Date:  2022-05-10

3.  Insights into dental mineralization from three heritable mineralization disorders.

Authors:  Michael B Chavez; Kaitrin Kramer; Emily Y Chu; Vivek Thumbigere-Math; Brian L Foster
Journal:  J Struct Biol       Date:  2020-08-03       Impact factor: 2.867

Review 4.  Burosumab for Pediatric X-Linked Hypophosphatemia.

Authors:  Erik A Imel
Journal:  Curr Osteoporos Rep       Date:  2021-05-10       Impact factor: 5.163

Review 5.  Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.

Authors:  Michaël R Laurent; Jean De Schepper; Dominique Trouet; Nathalie Godefroid; Emese Boros; Claudine Heinrichs; Bert Bravenboer; Brigitte Velkeniers; Johan Lammens; Pol Harvengt; Etienne Cavalier; Jean-François Kaux; Jacques Lombet; Kathleen De Waele; Charlotte Verroken; Koenraad van Hoeck; Geert R Mortier; Elena Levtchenko; Johan Vande Walle
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-19       Impact factor: 5.555

6.  Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial.

Authors:  Noriyuki Namba; Takuo Kubota; Koji Muroya; Hiroyuki Tanaka; Masanori Kanematsu; Masahiro Kojima; Shunichiro Orihara; Hironori Kanda; Yoshiki Seino; Keiichi Ozono
Journal:  J Endocr Soc       Date:  2022-02-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.